Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 12:05PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.67 Insider Own62.86% Shs Outstand55.14M Perf Week15.34%
Market Cap111.97M Forward P/E- EPS next Y-1.12 Insider Trans0.00% Shs Float20.48M Perf Month0.00%
Income-92.28M PEG- EPS next Q-0.37 Inst Own31.45% Short Float27.48% Perf Quarter-15.77%
Sales4.94M P/S22.67 EPS this Y28.49% Inst Trans0.24% Short Ratio11.33 Perf Half Y-45.06%
Book/sh0.75 P/B2.71 EPS next Y12.85% ROA-54.28% Short Interest5.63M Perf Year-61.41%
Cash/sh1.09 P/C1.87 EPS next 5Y- ROE-112.29% 52W Range1.30 - 6.30 Perf YTD-32.56%
Dividend Est.- P/FCF- EPS past 5Y-48.08% ROI-60.32% 52W High-67.78% Beta1.89
Dividend TTM- Quick Ratio2.87 Sales past 5Y347.21% Gross Margin-47.40% 52W Low56.15% ATR (14)0.18
Dividend Ex-Date- Current Ratio2.87 EPS Y/Y TTM24.71% Oper. Margin-1921.30% RSI (14)48.98 Volatility7.46% 9.50%
Employees94 Debt/Eq3.09 Sales Y/Y TTM112.70% Profit Margin-1868.35% Recom1.17 Target Price10.50
Option/ShortYes / Yes LT Debt/Eq2.70 EPS Q/Q26.90% Payout- Rel Volume0.47 Prev Close2.09
Sales Surprise102.70% EPS Surprise-8.14% Sales Q/Q357.36% EarningsMay 06 BMO Avg Volume496.72K Price2.03
SMA20-2.22% SMA50-4.47% SMA200-24.22% Trades Volume99,369 Change-2.87%
Date Action Analyst Rating Change Price Target Change
Jun-18-24Initiated Raymond James Outperform $12
May-25-23Resumed Jefferies Buy $18 → $15
Dec-08-22Initiated H.C. Wainwright Buy $11
Sep-23-22Initiated Chardan Capital Markets Buy $12
Today 08:00AM
Jun-24-24 07:00AM
Jun-12-24 07:00AM
May-30-24 07:00AM
May-29-24 07:00AM
07:00AM Loading…
May-09-24 07:00AM
May-08-24 07:00AM
May-06-24 02:52PM
Apr-25-24 10:02AM
Apr-23-24 07:00AM
Apr-17-24 09:55AM
Apr-09-24 07:00AM
Apr-08-24 08:00AM
12:00PM Loading…
Apr-03-24 12:00PM
Mar-28-24 11:54PM
Mar-19-24 08:30AM
Mar-06-24 07:00AM
Jan-09-24 11:01PM
Jan-08-24 06:30AM
Jan-05-24 12:55PM
Jan-04-24 06:08PM
06:00AM Loading…
Jan-02-24 04:05PM
Dec-04-23 04:00PM
Nov-27-23 07:01PM
Nov-21-23 06:00AM
Nov-20-23 04:00PM
Nov-13-23 07:00AM
Nov-09-23 07:00AM
Nov-07-23 04:00PM
Nov-01-23 10:30AM
Oct-31-23 07:00AM
Oct-19-23 10:30AM
Oct-16-23 07:00AM
Oct-11-23 04:00PM
Oct-04-23 04:00PM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-26-23 07:00AM
Sep-25-23 04:00PM
Sep-21-23 04:00PM
Sep-11-23 06:30AM
Aug-29-23 07:00AM
Aug-05-23 08:05AM
Aug-03-23 05:15PM
Jul-20-23 07:39AM
Jul-18-23 09:43AM
Jul-12-23 07:00AM
Jul-03-23 11:20AM
Jun-22-23 09:18AM
Jun-14-23 11:48AM
Jun-08-23 11:49AM
Jun-06-23 12:13PM
Jun-01-23 07:00AM
May-31-23 08:30AM
May-25-23 09:55AM
May-16-23 06:00AM
May-10-23 07:34AM
May-09-23 09:55AM
May-04-23 08:35AM
Apr-27-23 07:00AM
Apr-13-23 06:33AM
Apr-06-23 04:01AM
Mar-30-23 07:00AM
Mar-17-23 03:35AM
Mar-03-23 05:01AM
Mar-01-23 08:35AM
Feb-23-23 07:00AM
Feb-10-23 04:11AM
Jan-17-23 07:00AM
Dec-08-22 01:24PM
Nov-28-22 09:55AM
Nov-17-22 07:00AM
Nov-15-22 07:00AM
Nov-11-22 09:55AM
Nov-10-22 05:57AM
Nov-08-22 07:00AM
Nov-03-22 07:00AM
Nov-02-22 07:00AM
Oct-27-22 07:00AM
Oct-12-22 07:00AM
Sep-26-22 07:00AM
Sep-06-22 07:00AM
Sep-01-22 07:00AM
Aug-04-22 07:00AM
Aug-03-22 07:00AM
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.